27.05
-0.14 (-0.51%)
| 前收盘价格 | 27.19 |
| 收盘价格 | 27.01 |
| 成交量 | 738,504 |
| 平均成交量 (3个月) | 2,040,927 |
| 市值 | 2,807,294,464 |
| 价格/销量 (P/S) | 72.72 |
| 股市价格/股市净资产 (P/B) | 6.88 |
| 52周波幅 | |
| 利润日期 | 8 Oct 2026 |
| 营业利益率 (TTM) | -340.67% |
| 稀释每股收益 (EPS TTM) | -2.60 |
| 季度收入增长率 (YOY) | 11.30% |
| 总债务/股东权益 (D/E MRQ) | 5.54% |
| 流动比率 (MRQ) | 6.26 |
| 营业现金流 (OCF TTM) | -191.72 M |
| 杠杆自由现金流 (LFCF TTM) | -106.56 M |
| 资产报酬率 (ROA TTM) | -31.08% |
| 股东权益报酬率 (ROE TTM) | -64.16% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Nurix Therapeutics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.33 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.41% |
| 机构持股比例 | 111.85% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合